Quarterly UpdatesJul 7, 2026, 04:06 PM
Nyxoah Q2 Preliminary Revenue €7.7M; CMS Proposes 12-15% Reimbursement Hike
AI Summary
Nyxoah SA announced preliminary unaudited second quarter 2026 results, with global net revenue expected to reach €7.7 million and U.S. net revenue at €5.2 million, both reflecting over 20% sequential growth. The company also highlighted positive proposed reimbursement increases from CMS for its Genio procedure, with hospital reimbursement potentially rising by 12% and ASC reimbursement by 15%. Nyxoah secured $110 million in new financing and reiterated its full-year 2026 revenue guidance of €36 million to €40 million.
Key Highlights
- Global net revenue expected to be approximately €7.7 million in Q2 2026.
- U.S. net revenue expected to be approximately €5.2 million in Q2 2026.
- CMS proposes 12% increase for hospital reimbursement (C8011) to $35,414.
- CMS proposes 15% increase for ASC reimbursement to $31,722.
- $110 million in aggregate financing secured in Q2.
- Cash, cash equivalents, and financial assets approximately €97.8 million as of June 30, 2026.
- 55 new surgeons trained in Q2, totaling 262 surgeons.
- Full-year 2026 global net revenue guidance remains €36 million to €40 million.
Price Impact
More from NYXH